You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Let's Talk Relapsed/Refractory Chronic Lymphocytic Leukemia: Expert Perspectives on Reversible BTK Inhibitors

  • Authors: Barbara F. Eichhorst, MD; Nicole Lamanna, MD
  • CME / ABIM MOC Released: 4/12/2023
  • Valid for credit through: 4/12/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This educational activity is intended for hematology/oncology specialists, pathologists, and oncology care teams.

The goal of this activity is for learners to be better able to understand the rationale, available data and ongoing trials with reversible, non-covalent Bruton tyrosine kinase (BTK) inhibitors for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanistic differences between covalent and noncovalent BTK inhibitors
    • Clinical data with emerging noncovalent BTK inhibitors for the treatment of R/R CLL/SLL
  • Demonstrate greater confidence in my ability to

    • Understand the potential place of emerging non-covalent BTK inhibitors for the management of patients with R/R CLL/SLL


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Barbara F. Eichhorst, MD

    Associate Professor
    Consultant Hematologist
    Department for Internal Medicine
    Secretary of the GLLSG
    University Hospital of Cologne
    Cologne, Germany

    Disclosures

    Barbara F. Eichhorst, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie, Inc.; AstraZeneca; BeiGene (Beijing) Co., Ltd.; Bristol Myers Squibb Company; Eli Lilly and Company; Janssen; Merck Sharp & Dohme
    Speaker or member of speakers bureau for: AbbVie, Inc.; AstraZeneca; BeiGene (Beijing) Co., Ltd.; Janssen; Merck Sharp & Dohme; Roche
    Research funding from: AbbVie, Inc.; AstraZeneca; BeiGene (Beijing) Co., Ltd.; Gilead Sciences, Inc.; Janssen; Roche

  • Nicole Lamanna, MD

    Associate Professor of Medicine 
    Director of CLL Program
    Columbia University
    New York, New York, United States

    Disclosures

    Nicole Lamanna, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie, Inc.; Adaptive Biotechnologies; AstraZeneca; BeiGene (Beijing) Co., Ltd.; Genentech; Janssen; Pharmacyclics, Inc.
    Research funding from: AbbVie, Inc.; AstraZeneca; BeiGene (Beijing) Co., Ltd.; Genentech; Janssen; Lilly; Loxo Oncology; MindSight; Octapharma; Oncternal; Pharmacyclics, Inc.; TG Therapeutics, Inc.

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Sanneke Koekkoek has no relevant financial relationships.

  • Chii Shyang Fong, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Chii Shyang Fong, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Developed through a collaboration between The Leukemia & Lymphoma Society and Medscape Oncology.

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Let's Talk Relapsed/Refractory Chronic Lymphocytic Leukemia: Expert Perspectives on Reversible BTK Inhibitors

Authors: Barbara F. Eichhorst, MD; Nicole Lamanna, MDFaculty and Disclosures

CME / ABIM MOC Released: 4/12/2023

Valid for credit through: 4/12/2024, 11:59 PM EST

processing....

Transkription in Deutsch

Download the pdf.

« Return to: Let's Talk Relapsed/Refractory Chronic Lymphocytic Leukemia: Expert Perspectives on Reversible BTK Inhibitors
  • Print